MicroQuin, a biotechnology startup, used the International Space Station (ISS) National Laboratory to grow 3D breast and prostate cancer cell cultures to learn more about how these cancers develop and grow. Via MicroQuin’s ISS National…
Continue Reading
Leeds Teaching Hospitals NHS Trust (LTHT) is piloting an AI solution, designed by Lucida Medical, to assess whether it can improve prostate cancer diagnosis.
The one-month pilot, which began in August 2024, is testing the effectiveness…
Detecting Prostate Cancer with Revolutionary AI Tool
The integration of artificial intelligence (AI) in healthcare has revolutionized the way medical professionals diagnose and treat various diseases. A new study published in BJUI Compass confirms the…
What You Should Know:
– Avenda Health, a pioneer in AI-powered prostate cancer care, announced today that the Centers for Medicare & Medicaid Services (CMS) has assigned a national payment rate for its prostate cancer…
Continue Reading
What You Should Know:
– GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence (AI) solutions, is excited to introduce MIM Symphony HDR Prostate to support high dose-rate (HDR) brachytherapy.
– This innovative solution aims…
Continue Reading
Introduction
Lantheus Holdings, Inc., a renowned radiopharmaceutical-focused company, has made a significant stride in the cancer care sector by acquiring the global rights to Life Molecular Imaging’s RM2. This novel therapeutic and diagnostic pair targets…
The current prostate cancer (PCa) screen test, prostate-specific antigen (PSA), has a high sensitivity for PCa but low specificity for high-risk, clinically significant PCa (csPCa), resulting in overdiagnosis and overtreatment of non-csPCa. Early identification…
Continue Reading
Introduction
Artificial Intelligence (AI) continues to revolutionize the medical field, offering unprecedented advancements in diagnostics and treatment. A new study by Avenda Health, published in The Journal of Urology, demonstrates AI’s remarkable capability to enhance…
By Shania Kennedy
June 04, 2024 – A research team from Moffitt Cancer Center and the University of Oxford has created a deep learning framework to help personalize adaptive therapy schedules for patients with prostate cancer.
The…
What You Should Know:
– Blue Earth Diagnostics, a Bracco company and leader in innovative PET radiopharmaceuticals, announced a data-sharing agreement with Siemens Healthineers.
– This collaboration focuses on anonymized data from Blue Earth’s Phase 3…
Continue Reading
